Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRA

- PMLiVE

Takeda spends $230m on oncology biotech deal

Buys into ImmunoGen’s antibody-drug conjugate technology

- PMLiVE

Takeda’s Entyvio recommended by NICE for bowel disease

But must supply the drug at a discounted rate to the NHS

Takeda appoints Christophe Weber as its new CEO

Frenchman had been widely expected to succeed Yasuchika Hasegawa

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

- PMLiVE

Takeda grows in Turkey with Neutec subsidiary acquisition

Will acquire Toplam Kalite for up to 300m Turkish lira

- PMLiVE

Merck takes promotional responsibility for Erbitux in Japan

Currently co-promotes the drug withBristol-Myers Squibb

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

- PMLiVE

Takeda’s ‘oral Velcade’ clears first phase III hurdle

Ixazomib shows early stage promise for myeloma

Novartis building

Novartis’ Japanese subsidiary threatened with suspension

Company failed to report more than 3,200 adverse events among patients taking its drugs

- PMLiVE

ICON to open global innovation hub in Ireland

Will create 200 new jobs

- PMLiVE

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links